Table 1.
NET patient demographics
| Site | No. | Age Median range |
Gender (M/F) |
Grade | Mets | IPD | Clinical Status | CgA* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | G2 | G3 | TC | AC | ND | No. | % | No. | % | NED/CR | SD | PD | ND | No. | % | ||||
| Appx. | 56 | 42 (18-56) | 14:42 | 28 | 11 | 4** | 13 | 11 | 20% | 23 | 41% | 19 | 31 | 6 | 0 | 26 | 46% | ||
| Colon | 23 | 59.5 (38-83) | 7:16 | 8 | 7 | 1 | 7 | 18 | 78% | 19 | 82% | 2 | 11 | 9 | 1 | 10 | 43% | ||
| CUP | 81 | 62 (25-82) | 38:43 | 11 | 27 | 9 | 34 | 60 | 74% | 75 | 93% | 4 | 32 | 31 | 14 | 41 | 51% | ||
| Duod. | 36 | 57 (30-87) | 20:16 | 17 | 5 | 1 | 13 | 23 | 64% | 30 | 83% | 4 | 21 | 7 | 4 | 25 | 69% | ||
| Stomach | 76 | 60 (11-88) | 24:52 | 45 | 13 | 7 | 11 | 16 | 21% | 25 | 33% | 50 | 15 | 10 | 1 | 56 | 74% | ||
| Lung | 301 | 62 (18-87) | 107:194 | 3 | 142 | 131 | 25 | 129 | 43% | 256 | 85% | 37 | 125 | 123 | 6 | 137 | 44% | ||
| Pancreas | 359 | 58 (15-87) | 179:180 | 105 | 152 | 30 | 72 | 233 | 65% | 309 | 86% | 29 | 133 | 152 | 26 | 253 | 70% | ||
| PPGL | 121 | 36 (10-64) | 58:63 | 10 | 2 | 119 | 35 | 29% | 117 | 97% | 4 | 81 | 36 | 0 | 0 | 0% | |||
| Rectum | 88 | 56 (21-82) | 47:38 | 52 | 18 | 3 | 15 | 29 | 33% | 39 | 44% | 42 | 19 | 20 | 7 | 65 | 74% | ||
| SI | 521 | 62 (22-87) | 257:264 | 272 | 139 | 7 | 103 | 443 | 85% | 464 | 89% | 36 | 254 | 172 | 11 | 296 | 57% | ||
| Others # | 22 | 66.5 (38-77) | 7:15 | 2 | 7 | 3 | 9 | 19 | 86% | 21 | 95% | 1 | 9 | 11 | 1 | 13 | 59% | ||
AC = atypical carcinoid. App. = appendix. CR = complete remission. CUP = carcinoid of unknown primary. Duod. = duodenum. IPD = image-positive disease. ND = no data. NED = no evidence of disease. PD = progressive disease. PPGL = pheochromocytomas and paragangliomas. SD = Stable disease. SI = small intestine. TC = typical carcinoid.
*
These are included in Cohort 2.
**
4: 3 were goblet cell carcinoids
#
including ovarian, pituitary, testicular and thymic NETs.